BIOCON Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > biocon

Technical Analysis

Technical Strength: 8.1 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 68.6. According to RSI analysis, biocon is technically strong. 9.0 BIOCON RSI Chart
MACD (?) MACD: 29.3 and Signal Line: 29.1. According to MACD analysis, a bullish crossover just happend and it's a positive signal. 8.0 BIOCON MACD Chart
Simple Moving Average (?) According to simple moving average analysis, biocon is in a strong uptrend. Major support levels are 1052.805, 996.884, 866.618. 10.0 BIOCON Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, biocon is in a strong uptrend. Major support levels are 1057.278, 1009.804, 866.1685. 10.0 BIOCON Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.843. According to bollinger bands, biocon is technically strong. 7.0 BIOCON Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 1030.8234 and 1002.35. Resistance level is 1123.0. 6.5 BIOCON Fibonacci Retracement Chart
Average True Range (?) ATR: 28.5 NA BIOCON Average True Range Chart
Average Directional Index (?) ADX is 33.2 which means BIOCON is in a trend. NA BIOCON Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
February 17, 2017
Open Price 1109.0
High Price 1123.0
Low Price 1102.0
Close Price 1105.35
Absolute Change 10.05
Percentage Change 0.918%
Weekly Change 1.49%
Monthly Change 11.3%
Yearly Change 149%
52-week high 1123.0
52-week low 431.0
Corporate Actions
ExDate Purpose
June 22, 2016 ANNUAL GENERAL MEETING
March 17, 2016 INT DIV-RS 5 PER SHARE
March 17, 2016 INTERIM DIVIDEND
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.757
Confidence in Beta5.49%
Market Capital Rs. 22104.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 43.67
TTM Price-to-Earnings (P/E) Ratio 25.3
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 17 February 2017: Deliverable Quantity:1.12e+05 NA BIOCON Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 17 February 2017: Daily Volatility:0.3362 NA BIOCON Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 17 February 2017: PCR_OI:0.764 PCR:0.318 NA BIOCON PCR Chart
Premium (?) 17 February 2017 Premium: 0.15 Futures OI:2356800.0 NA BIOCON Premium Chart
Option_MAX_OI (?) 17 February 2017: Price:1105.35 Put with maximum OI:1080.0 Call with maximum OI:1100.0 NA BIOCON Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
February 23, 2017 1105.5 2356800.0 3235.0 3509.0 1105.35
March 30, 2017 1111.65 400200.0 350.0 450.0 1105.35
April 27, 2017 1117.0 7200.0 1.0 1.0 1105.35

Option Chains - NSE

BIOCON Option Zone

Announcements

February 17, 2017 BiocPress Releasecon Limited has informed the Exchange regarding a press release dated February 16, 2017, titled "U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon s Proposed Biosimilar Pegfilgrastim for Review".
February 14, 2017 BiocAnalysts/Institutional Investor Meet/Con. Call Updatescon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
See all Announcements

Board Meetings

Date Meeting Date Purpose
December 27, 2016 January 24, 2017 InteResults/Otherser alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended December 31, 2016 amongst other routine matters.
October 07, 2016 October 20, 2016 inteResultser alia, to approve the un-audited financial results for the quarter and period ended on September 30, 2016.
See all Board Meetings

BIOCON is part of...

Index Weightage
CNXMIDCAP 0.6
CNX500 0.08

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 1076 Rs. 1089 Rs. 1097 Rs. 1110 Rs. 1118 Rs. 1131 Rs. 1139